 | Up a level |
Moccia, A A; Aeppli, S; Güsewell, S; Bargetzi, M; Caspar, C; Brülisauer, D; Ebnöther, M; Fehr, M; Fischer, N; Ghilardi, G; Krasniqi, F; Lang, N; Mey, U; Mingrone, W; Novak, U; Pfleger, C; Richter, P; Rütti, M; Schmidt, A; Stenner, F; ... (2021). Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. Hematological oncology, 39(2), pp. 196-204. Wiley 10.1002/hon.2830
Hitz, F; Kraus, M; Pabst, Thomas; Hess, D; Besse, L; Silzle, T; Novak, Urban; Seipel, Katja; Rondeau, S; Stüdeli, S; Vilei, S Berardi; Samaras, P; Mey, U; Driessen, C (2019). Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10). Blood cancer journal, 9(9), p. 70. Springer Nature 10.1038/s41408-019-0228-2
Hitz, F; Fischer, N; Pabst, Th; Caspar, C; Berthod, G; Eckhardt, K; Berardi Vilei, S; Zucca, E; Mey, U; On behalf of Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland (2013). Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial. Annals of hematology, 92(8), pp. 1033-1040. Berlin: Springer 10.1007/s00277-013-1751-z
Taverna, C; Bargetzi, M; Betticher, D; Gmür, J; Gregor, M; Heim, D; Hess, U; Ketterer, N; Lerch, E; Matthes, T; Mey, U; Pabst, T; Renner, C (2010). Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. Swiss medical weekly, 140, w13054. Muttenz: EMH Schweizerischer Ärzteverlag 10.4414/smw.2010.13054
